New clinical data advances stem cell-based cell therapy for Parkinson's disease

New objective information from the STEM-PD Phase I/II objective proceedings person been presented astatine the ISSCR 2026 Annual Meeting. The survey reports 12-month outcomes evaluating a cryopreserved, off-the-shelf dopaminergic progenitor compartment merchandise derived from quality pluripotent stem cells for the attraction of Parkinson's disease.